11th World ADC Europe 2021

Memo

Now in its 11th year, World ADC Europe prides itself in being the industry-leading conference to help forward thinking researchers from the pharmaceutical, biotech and academic community advance the development of antibody-drug conjugates. Since the last World ADC London in March of 2020, we have seen huge progress within the ADC field with the approval of Trodelvy from Immunomedics, Blenrep from GSK - and now with ADC Therapeutics submitting their BLA in September of 2020, could this be the next approved ADC? Join fellow experts virtually across 140+ active organisations as they unite at this industry focussed digital conference to learn the latest ADC intelligence, foster new connections and develop business relationships with partners. This year, you can be part of Europe's longest standing and most comprehensive ADC conference from the comfort and safety of your workplace and continue to power the development of your ADC pipeline in 2021. For more information, visit: www.worldadc-europe.com URLs:Tickets: https://go.evvnt.com/698116-1?pid=5569 Brochure: https://go.evvnt.com/698116-2?pid=5569  Date and Time: On Monday March 08, 2021 at 9:00 am (ends Thursday March 11, 2021 at 5:00 pm) Prices:Drug Developer Pricing - Conference (2 Day Pass): GBP 1499.00,Service Provider Pricing - Conference (2 Day Pass): GBP 1799.00,Academic Pricing - Conference Only - Conference (2 Day Pass): GBP 1199.00 Speakers: Adam Taylor, Scientist, Defence Science and Technology Laboratory - DSTL, Agnieska Czechowicz, Assistant Professor of Pediatrics, Stanford University School of Medicine, Alain Beck, Senior Director, Biologics CMC and developability, Pierre Fabre, Anand Subramony, Vice President, Antibody Discovery and Protein Engineering, R and D, AstraZeneca, Andre Dumetz, Senior Scientific Investigator, GlaxoSmithKline, Arturo Molina, Chief Medical Officer, Sutro Biopharma, Bob Bayer, Director of CMC Drug Development, Tanabe Research Laboratories, Bob Liu, Senior Scientist, CytomX, Brian Lannuttim, Senior Vice President - Research and Development, Velosbio, Brian Mendelsohn Director, Process Development and Tech Transfer, Ajinomoto Bio-Pharma Services, Christopher Scott, Professor - Pharmaceutical Biosciences Queen's University, Belfast, David Newman, Independent Consultant, Donald Mager, Professor and Vice Chair of Pharmaceutical Sciences, University at Buffalo, Dorota Roberts, Associate Director Technical Product Steward - Biologics, Seattle Genetics, Ed Ha, Founding Principal Scientist, AngieX, Elizabeth Love, Senior Scientist - Drug conjugates, Biologics and Analysis, LideArc, Francesca Zammarchi, Head of Pharmacology, ADC Therapeutics, Futa Mimoto, Research Manager, Chugai Pharmaceuticals, Gareth Thomas, Professor - Experimental Pathology, University of Southampton, Gavin Bennett, Director and Project Leader, Bicycle Therapeutics, Gilles Gallant, Senior Vice President, Global Head of Oncology Development, Oncology R and D Daiichi Sankyo, Giorgio Salciarini, Technical Business Development Manager, BSP Pharmaceuticals, Gordon Rigg, Principal Consultant, Apex Biologics Consulting, Ian Schwartz, Global Biconjugate and Antibody-Drug Conjugates Consultant. Sartorius, Horst Bierau, Senior Scientific Advisor – Head CMC Science and Intelligence, Merck, Jia He, Analyst, Beacon Target Therapies, John Harlan, Senior Principal Research Scientist, AbbVie, John Lambert, Independent Consultant, Attager Consulting, Jon Van Dyck, Scientist, Seattle Genetics, Jostein Dahl, Chief Scientific Officer, Nordic Nanovector, Krista Kinneer, Senior Scientist, AstraZeneca, Lolke de haan, Head of Toxicology, ADC Therapeutics, Maria Laura Greco, Marie Curie Research Fellow, AstraZeneca, Marie Leman, Drug Product Team Leader and Tech Transfer Leader, Sanofi, Naresh Jain, President and Chief Executive Officer, NJ Biopharmaceuticals LLC, Nathan Ihle, Vice President - Chemistry, Manufacturing, Controls and Quality, Bolt Biotherapeutics, Nithyanandan Nagercoil, Expert Medical Assessor, Medicines and Healthcare Products Regulatory Agency (MHRA), Phil Howard, Chief Scientific Officer, Spirogen, Rick Powers, Independent Consultant, Robert Straubinger, Professor of Pharmaceutical Sciences, University at Buffalo, Roger Beerli, Chief Scientific Officer, NBE-Therapeutics, Romas Kudirka, Associate Director, Bolt Biotherapeutics, Salaheldin Hamed, Pharmacologist, FDA, Sally Ward, Director of Translational Immunology, Centre for Cancer Immunology, University of Southampton, Samuele Cazzamalli, Research Scientist, Philogen, Shelley Ackerman, Senior Scientist, Bolt Biotherapeutics, Simon Chivers, Independent Consultant, Steffen Wöll, Principle Scientist, Merck, Steve Conlan, Professor, University of Swansea, Thomas Nittoli, Director, R and D Chemistry Therapeutic Proteins, Regeneron, Thomas Pillow, Senior Scientist, Genentech, Toby Eyre, Haematology Consultant, Oxford University Hospitals NHS Foundation Trust, Torbjörn Gräslund, Professor in Medical Protein Technology, KTH Royal Institute of Technology, Ulf Grawunder, Chief Executive Officer and Founder, NBE Therapeutics, Victoria Wei, Associate Director, Johnson and Johnson, Vijay Chudasama, Professor of Organic Chemistry and Chemical Biology, University College London, William Goundry, Principal Scientist, AstraZeneca